ES2570973T3 - Productos y métodos para la estimulación de una respuesta inmunitaria - Google Patents

Productos y métodos para la estimulación de una respuesta inmunitaria

Info

Publication number
ES2570973T3
ES2570973T3 ES13189439T ES13189439T ES2570973T3 ES 2570973 T3 ES2570973 T3 ES 2570973T3 ES 13189439 T ES13189439 T ES 13189439T ES 13189439 T ES13189439 T ES 13189439T ES 2570973 T3 ES2570973 T3 ES 2570973T3
Authority
ES
Spain
Prior art keywords
immune response
lymphocyte
antigen
stimulating
products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13189439T
Other languages
English (en)
Inventor
Facundo Batista
Julia Eckl-Dorna
Patricia Barral
Vincenzo Cerundolo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of ES2570973T3 publication Critical patent/ES2570973T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un metodo para provocar in vitro una respuesta inmunitaria especifica del antigeno, comprendiendo el metodo la etapa de poner en contacto in vitro un linfocito B con un producto que comprende: (i) una perla de polimero o de silice que tiene un tamano de desde 1 nm hasta 10 μm; (ii) un antigeno de union al receptor de linfocitos B fijado a la superficie de la perla, y (iii) un inmunoestimulante fijado a la superficie de la perla, en donde el inmunoestimulante es α- galactosilceramida (αGal-Cer) o un oligodesoxinucleotido CpG (ODN);@ en el que el producto es internalizado por un linfocito B para provocar una respuesta inmunitaria mediada por BCR especifica del antigeno frente a dicho antigeno de union al receptor de linfocitos B.
ES13189439T 2008-05-02 2009-05-05 Productos y métodos para la estimulación de una respuesta inmunitaria Active ES2570973T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4981408P 2008-05-02 2008-05-02

Publications (1)

Publication Number Publication Date
ES2570973T3 true ES2570973T3 (es) 2016-05-23

Family

ID=40888253

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13189439T Active ES2570973T3 (es) 2008-05-02 2009-05-05 Productos y métodos para la estimulación de una respuesta inmunitaria

Country Status (9)

Country Link
US (1) US20110280930A1 (es)
EP (3) EP2711021B1 (es)
JP (3) JP5721620B2 (es)
CN (1) CN102170903B (es)
AU (1) AU2009241645B2 (es)
CA (1) CA2723226A1 (es)
ES (1) ES2570973T3 (es)
HK (3) HK1161542A1 (es)
WO (1) WO2009133378A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2711021B1 (en) * 2008-05-02 2016-03-09 BliNK Therapeutics Limited Products and methods for stimulating an immune response
EP2654779B1 (en) 2010-12-23 2018-02-28 Ludwig Institute for Cancer Research, Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof
TW201442739A (zh) * 2013-02-27 2014-11-16 Riken 過敏疾病治療藥
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
ES2750608T3 (es) 2013-07-25 2020-03-26 Exicure Inc Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico
WO2015021390A2 (en) 2013-08-08 2015-02-12 The Regents Of The University Of California Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
WO2015084677A1 (en) * 2013-12-02 2015-06-11 Arytha Biosciences, Llc Toxoid preparation and uses thereof
CN106163504B (zh) 2014-03-20 2021-02-09 加利福尼亚大学董事会 水凝胶毒素-吸收或结合纳米颗粒
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
TR201908550T4 (tr) * 2014-06-04 2019-07-22 Exicure Inc Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
EP3280464A4 (en) * 2015-04-10 2018-09-26 President and Fellows of Harvard College Immune cell trapping devices and methods for making and using the same
CN107530285B (zh) 2015-04-29 2021-07-27 加利福尼亚大学董事会 使用纳米粒子解毒
EP3307328A1 (en) * 2015-06-10 2018-04-18 Universität des Saarlandes Means and methods for treatment of b-cell malignancies
CN109072197A (zh) 2016-02-06 2018-12-21 哈佛学院校长同事会 重塑造血巢以重建免疫
NL2017204B1 (en) * 2016-06-08 2017-12-18 Kei International Ltd Solid substrate comprising antigens immobilised thereto, biosensor comprising said solid substrate and method for detecting the presence of mycobacterial material in a sample
WO2017211314A1 (en) 2016-06-08 2017-12-14 Kei International Limited Method for detecting presence of mycobacterial material in sample using immobilised mannosyl phosphoketide antigen
WO2018013797A1 (en) 2016-07-13 2018-01-18 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
EP3500275A4 (en) * 2016-08-17 2020-03-18 Orbis Health Solutions LLC BEAD VECTORS AGAINST TUMORS AND METHOD FOR USE THEREOF
WO2019032862A1 (en) * 2017-08-10 2019-02-14 Dana-Farber Cancer Institute, Inc. CELLS EXPRESSING LMP1 AND METHODS OF USE
EP3650466A1 (en) * 2018-11-12 2020-05-13 Consejo Superior De Investigaciones Científicas In vitro production of high affinity monoclonal antibodies
CN111229023B (zh) * 2018-11-29 2022-01-28 内蒙古东盛硅藻土科技创新产业园有限公司 一种化学降解添加剂
CN112300987B (zh) * 2020-10-16 2022-04-29 中国农业大学 单个浆细胞的筛选方法及其在小分子单克隆抗体制备中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
WO1993008306A1 (en) 1991-10-22 1993-04-29 Symbicom Aktiebolag Improvement in borrelia burgdorferi diagnosis and prophylaxis
ES2092560T5 (es) 1989-12-22 2004-09-16 Mikrogen Molekularbiologische Entwicklungs-Gmbh Proteinas inmunologicamente activas de borrelia burgdorferi, estuches de ensayo relacionados y vacuna.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992014488A1 (en) 1991-02-15 1992-09-03 Uab Research Foundation Structural gene of pneumococcal protein
EP0874051A3 (en) 1991-08-15 1998-11-04 SMITHKLINE BEECHAM BIOLOGICALS s.a. OSP a protein of borrelia burgdorferi subgroups, encoding genes and vaccines.
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US6004763A (en) * 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
JPH10507906A (ja) 1994-08-19 1998-08-04 ザ ジェネラル ホスピタル コーポレイション 遺伝子工学処理したブタ細胞
EP1434859A2 (en) * 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
DE10164309A1 (de) * 2001-12-28 2003-07-10 Fraunhofer Ges Forschung Verbesserte strukturiert-funktionale Bindematrices für Biomoleküle
JP2006505252A (ja) * 2002-08-14 2006-02-16 アヴィディス エスアー 抗原およびアジュバントの多量体複合体
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
JP2008504216A (ja) * 2003-12-02 2008-02-14 サイトイミューン サイエンシズ インコーポレイテッド モノクローナル抗体の生成のための方法および組成物
DK1767216T3 (da) 2004-06-11 2012-09-03 Riken Lægemiddel med regulatorisk celleligand indeholdt i liposom
CN1980638B (zh) * 2004-07-07 2011-10-12 国立血清研究所 用糖脂稳定基于脂质的佐剂制剂的组合物和方法
EP1793863B1 (en) * 2004-10-01 2017-04-12 Midatech Ltd. Nanoparticles comprising antigens and adjuvants capable of stimulating t helper cells
ATE438385T1 (de) * 2005-03-02 2009-08-15 Secr Defence Pharmazeutische zusammensetzung
EP1945651B1 (en) 2005-10-25 2014-06-25 The Ludwig Institute for Cancer Research Analogs of alpha galactosylceramide and uses thereof
US20070231344A1 (en) 2005-10-28 2007-10-04 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
WO2007051004A2 (en) 2005-10-28 2007-05-03 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
EP2711021B1 (en) * 2008-05-02 2016-03-09 BliNK Therapeutics Limited Products and methods for stimulating an immune response
JP5782775B2 (ja) 2011-03-29 2015-09-24 ソニー株式会社 情報表示装置および情報表示方法、並びにプログラム

Also Published As

Publication number Publication date
EP2711020A1 (en) 2014-03-26
JP5721620B2 (ja) 2015-05-20
JP2015038066A (ja) 2015-02-26
EP2711020B1 (en) 2016-08-10
CA2723226A1 (en) 2009-05-11
JP5853068B2 (ja) 2016-02-09
CN102170903B (zh) 2016-04-06
HK1161542A1 (zh) 2012-07-27
AU2009241645A1 (en) 2009-11-05
EP2288381A2 (en) 2011-03-02
HK1191548A1 (zh) 2014-08-01
EP2711021B1 (en) 2016-03-09
HK1190942A1 (zh) 2014-07-18
CN102170903A (zh) 2011-08-31
JP2011519847A (ja) 2011-07-14
EP2711021A1 (en) 2014-03-26
JP2015028023A (ja) 2015-02-12
WO2009133378A3 (en) 2009-12-23
AU2009241645B2 (en) 2014-07-17
US20110280930A1 (en) 2011-11-17
WO2009133378A2 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
ES2570973T3 (es) Productos y métodos para la estimulación de una respuesta inmunitaria
MY172421A (en) Immunostimulatory oligonucleotides
MX2010000781A (es) Metodo para adherir una pelicula sobre un sustrato curvo.
WO2008006504A3 (de) Verfahren zur herstellung optoelektronischer bauelemente und damit hergestellte erzeugnisse
TW200722101A (en) Novel composition
WO2010115122A3 (en) Generation of uniform fragments of nucleic acids using patterned substrates
EP1992479A4 (en) FILM SUBSTRATE OF A PRIMED SEPARATE FOIL, embossed release sheet, method of making a sheet stock from a sewn release sheet, method of making a sewn release sheet, a device for making a sewn release sheet, an artificial leather, and method of making an artificial leather
WO2010006753A3 (de) Siliciumdioxid-nanopartikel und deren verwendung zur vakzinierung
DK2468300T3 (da) Vaccinesammensætning indeholdende syntetisk adjuvant
CR10559A (es) Vacuna de influenza
AR072151A1 (es) Metodo para producir lentes de contacto de hidrogel de silicona
JP2012517268A5 (es)
JP2011519847A5 (es)
GB2431582A (en) Dendritic cell vaccines for treating cancer made from embryonic stem cells
EA201170194A1 (ru) Способ изготовления и сборки трехмерных изделий
UY31101A1 (es) Composición antigénica liofilizada
AR042549A1 (es) Un procedimiento para la preparacion de particulas de latex injertadas con polisacaridos
CL2011000914A1 (es) Vacuna combinada estable completamente liquida que comprende antigenos difterico, tetanico, pertusico acelular, de haemophilus influenzae, y de virus de poliomielitis en donde el antigeno se haemophilus influenzae no esta sustancialmente absorbido sobre ningun adyuvante; y proceso de fabricacion.
WO2008127296A3 (en) Methods and compositions for treating tularemia
WO2013160252A3 (en) Dry silicone gels and their methods of making using thiol-ene chemistry
CL2011003033A1 (es) Uso de un lipopolisacarido de ochrobactrum intermedium lmg3306 o de una composición que lo comprende para el tratamiento y/o prevencion de sepsis o enfermedades infecciosas; procedimiento para la preparacion del lipopolisacárido; y composicion que comprende el lipopolisacarido.
BRPI0817535B8 (pt) método in vitro eficiente para obter células apresentadoras de antígenos ativadas (apcs), especialmente células dendríticas (dcs), úteis na preparação de vacinas para o tratamento do câncer
BRPI0818718B8 (pt) processo de preparo de uma composição de vacina compreendendo antígeno e adjuvante na forma de látex inverso de homopolímero do ácido acrílico
WO2010044919A3 (en) Smallpox dna vaccine and the antigens therein that elicit an immune response
EP2506333A3 (en) Method for patterning a lacquer layer to hold electrical gridlines